The Human Proteome Organization Plasma Proteome Project pilot phase: reference specimens, technology platform...

Area of Science:

• Proteomics
• Biomarker Discovery
• Clinical Chemistry

Background:

• Circulating proteins are crucial for understanding health and disease.
• Developing reliable biomarkers for cancer prevention, diagnosis, and therapy requires comprehensive protein characterization.
• The Human Proteome Organization (HUPO) initiated the Plasma Proteome Project (PPP) to address these needs.

Purpose of the Study:

• To systematically characterize circulating proteins in health and disease.
• To compare the performance of various technology platforms for plasma proteome analysis.
• To evaluate different human plasma and serum specimens for proteomic studies.

Main Methods:

• Comparative analysis of multiple proteomic technology platforms.
• Assessment of ethylenediaminetetraacetic acid (EDTA), heparin, and citrate-anticoagulated plasma, alongside serum.
• Evaluation of protein identification numbers and platform interferences across specimen types.

Main Results:

• Identification of advantages and limitations for diverse proteomic technologies.
• Characterization of differences in protein profiles between plasma and serum specimens.
• Establishment of a foundational global knowledge base for plasma proteome data.

Conclusions:

• Systematic characterization of circulating proteins is essential for biomarker development.
• Understanding technology platform performance and specimen characteristics is key for reliable proteomic analysis.
• The HUPO PPP pilot phase provides a framework for a global plasma proteome data repository.